Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, and Policy Development of Medical Products for Ongoing Public Health Activities, U01 Clinical Trial Not Allowed
ID: 353528Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $700K

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353528

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-036.html
Timeline
    Description

    The U.S. Food and Drug Administration (FDA) is inviting applications for a cooperative agreement aimed at convening activities related to the processes, surveillance, and policy development of medical products to support ongoing public health initiatives. The primary objective is to engage a diverse range of stakeholders through meetings such as conferences and roundtables, facilitating discussions that explore and address critical issues in medical product policies and surveillance methods. This funding opportunity, which falls under the category of Food and Nutrition, has an estimated total program funding of $700,000, with applications due by June 17, 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information, and additional details can be found in the funding announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-036.html.

    Point(s) of Contact
    terrin.brown@fda.hhs.gov
    Files
    Title
    Posted
    RFA-FD-24-036.html
    The Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) from the U.S. Food and Drug Administration (FDA) aimed at soliciting applications from independent organizations to convene gatherings addressing medical product policies and surveillance methods. This initiative falls under the U01 Research Project Cooperative Agreements activity code and does not allow clinical trials. The FDA intends to provide up to $700,000 for a maximum of five years to support various stakeholder meetings, including conferences and roundtables that integrate diverse expertise while exploring key public health issues. Key objectives include planning and executing the forums, engaging with experts, and disseminating findings. Eligible applicants encompass a wide range of entities, from higher education institutions to non-profits and local governments. Applications are due by June 17, 2024, with a scientific peer review process scheduled for July 2024. The overarching goal is to foster collaborative discussions and gather diverse insights that will inform responsive FDA policies while ensuring public health safety and transparency throughout the process.
    Similar Opportunities
    Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further details.
    FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering grants under the R13 Clinical Trial Not Allowed program to support high-quality conferences and scientific meetings that align with its mission, particularly in public health. The objective of this funding opportunity is to facilitate research exchange on FDA-related topics through symposiums, seminars, workshops, or formal meetings, while ensuring that clinical trials are not funded under this grant. This initiative is crucial for fostering scientific dialogue and collaboration, enhancing public health outcomes, and promoting compliance with federal regulations. Interested applicants, including higher education institutions and nonprofits, can apply for a total estimated funding of $1,000,000, with up to 20 awards anticipated. Key deadlines for submission are set for April and October annually through 2025, and applicants must submit a Letter of Intent eight weeks prior to their application. For further inquiries, contact Janelle Fundersburg at janelle.fundersburg@fda.hhs.gov or by phone at 301-798-2533.
    Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F)," aimed at enhancing state manufactured food regulatory programs. This cooperative agreement seeks to support the development and maintenance of Manufactured Food Regulatory Program Standards (MFRPS) to ensure high-quality regulatory frameworks that improve food safety and reduce foodborne illness hazards. Eligible applicants include state, tribal, and territorial food safety programs with existing FDA food safety inspection contracts or those willing to enter into such contracts, with funding amounts ranging from $340,000 to $1,285,000 per year. Interested parties can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information, with applications expected to align with the fiscal year 2024 timeline.
    Manufactured Foods Flexible Funding Model (MF-FFM)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Manufactured Foods Flexible Funding Model (MF-FFM)" aimed at advancing a nationally integrated food safety system. This cooperative agreement seeks to support initiatives related to Manufactured Food Regulatory Program Standards (MFRPS), dietary supplement safety, and state compliance and enforcement infrastructure, with a focus on enhancing food safety practices across jurisdictions. The program is critical for ensuring that state regulatory programs maintain high-quality standards and best practices in food safety. Interested applicants, which include state, local, territorial, and tribal agencies, as well as non-profit training entities collaborating with higher education institutions, can reach out to Gordana Zuber at gordana.zuber@fda.hhs.gov or by phone at 301-348-1747 for further details. The estimated project start date is July 1, 2023, with approximately 50 awards expected under this discretionary funding opportunity.
    Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is announcing a funding opportunity for a Cooperative Agreement titled "Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)." This initiative aims to support research and development of practices that mitigate risks associated with nitrosamine impurities in human drugs, thereby enhancing public health safety while ensuring access to essential therapeutic drugs. The FDA seeks to fund one award with a total funding amount of $350,000, with no cost-sharing or matching requirements. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information. The opportunity is forecasted for fiscal year 2024, and applicants may submit multiple distinct applications, adhering to guidelines regarding overlapping submissions.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at facilitating federal financial assistance for high-quality conferences and scientific meetings that align with the FDA's mission. The program seeks to support events such as symposiums, seminars, and workshops that focus on public health issues relevant to the FDA's objectives, with an estimated total program funding of $1,000,000 and approximately 30 awards expected. Interested applicants, specifically small businesses, should note that non-domestic entities are ineligible, and applications must be submitted before the conference start date to be considered for funding. For further inquiries, applicants can contact Janelle Fundersburg at Janelle.Fundersburg@fda.hhs.gov or by phone at 301-796-2533.
    Drug Development Tools Research Grants (U01) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering Drug Development Tools Research Grants (U01) to support research aimed at advancing drug development tools (DDTs) that have an accepted or reviewable Letter of Intent within the FDA's qualification program. These grants are intended for developers working towards their qualification plan or full qualification package, focusing on tools that can enhance public health by optimizing the drug development process, such as biomarkers or animal models. The funding opportunity provides up to $500,000 for a maximum two-year period, with applications due by May 13, 2024, and May 13, 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information and are encouraged to review the detailed announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html.
    Center for Research on Complex Generics (U18) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the establishment of a Center for Research on Complex Generics through a cooperative agreement. This initiative aims to enhance collaboration with the generic drug industry, focusing on identifying scientific challenges in generic product development and facilitating research that supports the FDA's mission to improve patient access to high-quality, safe, and effective generic drugs. The Center will serve as a hub for coordination among FDA, academia, and industry stakeholders, conducting research, hosting workshops, and providing public access to research outcomes. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. The funding amount is set at $1.5 million, with one award anticipated for the fiscal year 2025.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This cooperative agreement aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) initiatives by promoting education, outreach, and public awareness regarding the use and potential risks associated with skin lightening products, such as hydroquinone. The funding is crucial for developing innovative, community-based strategies that will strengthen the scientific foundation for public health education on this topic. Interested applicants can apply for a funding amount of $250,000, with the opportunity forecasted for fiscal year 2025. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610.